

## Volume 29, 2018 Supplement 1

### EGFR Mutant Non-small-cell Lung Cancer

#### Editorial

Tyrosine kinase inhibition of EGFR: a successful history  
of targeted therapy for NSCLC since 20 years

*J. Vansteenkiste & E. Wauters*

**i1**

#### Reviews

Overview of current systemic management of  
EGFR-mutant NSCLC

*W.-H. Hsu, J. C.-H. Yang, T. S. Mok & H. H. Loong*

**i3**

Mechanisms of acquired resistance to first- and  
second-generation EGFR tyrosine kinase inhibitors

*D. Westover, J. Zugazagoitia, B. C. Cho, C. M. Lovly &  
L. Paz-Ares*

**i10**

Osimertinib and other third-generation EGFR TKI in  
EGFR-mutant NSCLC patients

*J. Remon, C. E. Steuer, S. S. Ramalingam & E. Felip*

**i20**

Molecular mechanisms of acquired resistance to  
third-generation EGFR-TKIs in EGFR T790M-mutant  
lung cancer

*C. Ricordel, L. Friboulet, F. Facchinetti & J.-C. Soria*

**i28**

Are liquid biopsies a surrogate for tissue EGFR  
testing?

*J. W. Goldman, Z. S. Noor, J. Remon, B. Besse &  
N. Rosenfeld*

**i38**